TG2: a credible therapeutic target in fibrotic diseasedue to its multifunctional roles

Martin Griffin; Zhuo Wang; Thomas Thibault; Colin Murdoch; Daniel Rathbone

doi:10.1007/s00726-015-2016-z

Abstract

The role of TG2 in fibrosis is reported to be related to two important effects. The first in mediating the deposition and accumulation of the fibrotic extracellular matrix (ECM) via its cross-linking of proteins like fibronectin, collagen I and collagen III; and the second, the activation of latent matrix bound TGFβ1. We report here that the role of TG2 in fibrosis progression can be much more complex.
We also report a new family of TG2-specific inhibitors that can not only inhibit protein cross-linking, but also regulate other functions of TG2, thus increasing their potency which can be demonstrated by their effectiveness in inhibiting fibrosis in two different fibrotic in vivo models.

Original language	English
Pages (from-to)	1629
Number of pages	1
Journal	Amino Acids
Volume	47
Issue number	8
Early online date	14 Jul 2015
DOIs	https://doi.org/10.1007/s00726-015-2016-z
Publication status	Published - 31 Aug 2015
Event	14th International Congress on Amino Acids, Peptides and Proteins - Vienna, Austria Duration: 3 Aug 2015 → 7 Aug 2015

Bibliographical note

Abstracts presented at the 14th International Congress on Amino Acids, Peptides and Proteins, Vienna (AT), August 3–7, 2015.

Access to Document

10.1007/s00726-015-2016-z

Cite this

@article{217021181eec4011b9c6868bad42c0da,

title = "TG2: a credible therapeutic target in fibrotic diseasedue to its multifunctional roles",

abstract = "The role of TG2 in fibrosis is reported to be related to two important effects. The first in mediating the deposition and accumulation of the fibrotic extracellular matrix (ECM) via its cross-linking of proteins like fibronectin, collagen I and collagen III; and the second, the activation of latent matrix bound TGFβ1. We report here that the role of TG2 in fibrosis progression can be much more complex. We also report a new family of TG2-specific inhibitors that can not only inhibit protein cross-linking, but also regulate other functions of TG2, thus increasing their potency which can be demonstrated by their effectiveness in inhibiting fibrosis in two different fibrotic in vivo models.",

author = "Martin Griffin and Zhuo Wang and Thomas Thibault and Colin Murdoch and Daniel Rathbone",

note = "Abstracts presented at the 14th International Congress on Amino Acids, Peptides and Proteins, Vienna (AT), August 3–7, 2015.; 14th International Congress on Amino Acids, Peptides and Proteins ; Conference date: 03-08-2015 Through 07-08-2015",

year = "2015",

month = aug,

day = "31",

doi = "10.1007/s00726-015-2016-z",

language = "English",

volume = "47",

pages = "1629",

journal = "Amino Acids",

issn = "0939-4451",

publisher = "Springer",

number = "8",

}

TY - JOUR

T1 - TG2: a credible therapeutic target in fibrotic diseasedue to its multifunctional roles

AU - Griffin, Martin

AU - Wang, Zhuo

AU - Thibault, Thomas

AU - Murdoch, Colin

AU - Rathbone, Daniel

N1 - Abstracts presented at the 14th International Congress on Amino Acids, Peptides and Proteins, Vienna (AT), August 3–7, 2015.

PY - 2015/8/31

Y1 - 2015/8/31

N2 - The role of TG2 in fibrosis is reported to be related to two important effects. The first in mediating the deposition and accumulation of the fibrotic extracellular matrix (ECM) via its cross-linking of proteins like fibronectin, collagen I and collagen III; and the second, the activation of latent matrix bound TGFβ1. We report here that the role of TG2 in fibrosis progression can be much more complex. We also report a new family of TG2-specific inhibitors that can not only inhibit protein cross-linking, but also regulate other functions of TG2, thus increasing their potency which can be demonstrated by their effectiveness in inhibiting fibrosis in two different fibrotic in vivo models.

AB - The role of TG2 in fibrosis is reported to be related to two important effects. The first in mediating the deposition and accumulation of the fibrotic extracellular matrix (ECM) via its cross-linking of proteins like fibronectin, collagen I and collagen III; and the second, the activation of latent matrix bound TGFβ1. We report here that the role of TG2 in fibrosis progression can be much more complex. We also report a new family of TG2-specific inhibitors that can not only inhibit protein cross-linking, but also regulate other functions of TG2, thus increasing their potency which can be demonstrated by their effectiveness in inhibiting fibrosis in two different fibrotic in vivo models.

U2 - 10.1007/s00726-015-2016-z

DO - 10.1007/s00726-015-2016-z

M3 - Conference abstract

SN - 0939-4451

VL - 47

SP - 1629

JO - Amino Acids

JF - Amino Acids

IS - 8

T2 - 14th International Congress on Amino Acids, Peptides and Proteins

Y2 - 3 August 2015 through 7 August 2015

ER -

TG2: a credible therapeutic target in fibrotic diseasedue to its multifunctional roles

Abstract

Bibliographical note

Access to Document

Fingerprint

Cite this